Moleculin Short Long Term Debt Total from 2010 to 2025

MBRX Stock  USD 1.05  0.02  1.87%   
Moleculin Biotech Short and Long Term Debt Total yearly trend continues to be fairly stable with very little volatility. Short and Long Term Debt Total is likely to outpace its year average in 2025. During the period from 2010 to 2025, Moleculin Biotech Short and Long Term Debt Total regression line of annual values had r-squared of  0.05 and arithmetic mean of  397,329. View All Fundamentals
 
Short and Long Term Debt Total  
First Reported
2015-09-30
Previous Quarter
506 K
Current Value
478 K
Quarterly Volatility
135.7 K
 
Yuan Drop
 
Covid
Check Moleculin Biotech financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Moleculin Biotech's main balance sheet or income statement drivers, such as Interest Income of 912.6 K, Depreciation And Amortization of 245.5 K or Interest Expense of 2.3 M, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 1.03. Moleculin financial statements analysis is a perfect complement when working with Moleculin Biotech Valuation or Volatility modules.
  
Check out the analysis of Moleculin Biotech Correlation against competitors.
For more information on how to buy Moleculin Stock please use our How to Invest in Moleculin Biotech guide.

Latest Moleculin Biotech's Short Long Term Debt Total Growth Pattern

Below is the plot of the Short Long Term Debt Total of Moleculin Biotech over the last few years. It is Moleculin Biotech's Short and Long Term Debt Total historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Moleculin Biotech's overall financial position and show how it may be relating to other accounts over time.
Short Long Term Debt Total10 Years Trend
Pretty Stable
   Short Long Term Debt Total   
       Timeline  

Moleculin Short Long Term Debt Total Regression Statistics

Arithmetic Mean397,329
Geometric Mean383,776
Coefficient Of Variation23.86
Mean Deviation69,237
Median450,000
Standard Deviation94,803
Sample Variance9B
Range415K
R-Value(0.23)
Mean Square Error9.1B
R-Squared0.05
Significance0.39
Slope(4,639)
Total Sum of Squares134.8B

Moleculin Short Long Term Debt Total History

2025404.9 K
2024358 K
2023574 K
2022451 K
2021159 K
2020277 K

About Moleculin Biotech Financial Statements

Moleculin Biotech investors use historical fundamental indicators, such as Moleculin Biotech's Short Long Term Debt Total, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Moleculin Biotech. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Short and Long Term Debt Total358 K404.9 K

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Moleculin Stock Analysis

When running Moleculin Biotech's price analysis, check to measure Moleculin Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Moleculin Biotech is operating at the current time. Most of Moleculin Biotech's value examination focuses on studying past and present price action to predict the probability of Moleculin Biotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Moleculin Biotech's price. Additionally, you may evaluate how the addition of Moleculin Biotech to your portfolios can decrease your overall portfolio volatility.